Cracking the mild, difficult and fiendish codes within and downstream of the EGFR to link diagnostics and therapeutics.
Over the last 45 years, I have been working on growth factors, their receptors and signal transduction mechanisms. This period has seen a tremendous growth in knowledge and technology, and all of this, together with a focus interest in oncology, has steered me along a path designed to understand growth factor signalling so that we can see how drugs that target signalling pathways might be able to control cancer. The knowledge that we already have is likely to lead to cures for many common cancers within the next 25 years.
Waterfield
M
M
Ludwig Institute for Cancer Research, University College London, London W1W 7BS, UK. mikew@ludwig.ucl.ac.uk
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004358:Drug Therapy / Q000379:methods; D066246:ErbB Receptors / Q000378:metabolism*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism; D008495:Medical Oncology / Q000379:methods / Q000639:trends*; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D015398:Signal Transduction
D000970:Antineoplastic Agents; D036341:Intercellular Signaling Peptides and Proteins; D066246:ErbB Receptors